Hot Stocks: Brokerage view on Mankind Pharma, Delhivery, Suzlon and ICICI Lombard

We have collated a list of recommendations from top brokerage firms from ETNow and other sources:

Motilal Oswal on ICICI Lombard: Buy| Target Rs 1550
Motilal Oswal maintained a buy rating on ICICI Lombard with a target price of Rs 1550.

According to the brokerage, the Indian insurance industry is undergoing radical transformations. With new reforms and initiatives being introduced by the IRDAI, the general insurance industry is poised for robust growth, riding on tech-driven disruptions.

“We revised our target multiple up from 26x to 30x FY25E EPS as the concern around ICICI Bank stake sale should now be behind. We reiterate our buy rating with a revised 1-year target price of Rs 1,550,” said the note.

Jefferies on Mankind Pharma: Initiate Hold| Target Rs 1830
Jefferies initiated a hold rating on Mankind Pharma with a target price of Rs 1830. The stock has delivered consistent market outperformance.

The brokerage said that levers are in place to sustain future outperformance. The company has a predictable and sustainable earnings profile. It is a strong franchise, but valuations limit further upside from current levels.

Bernstein on Delhivery: Initiate Outperform| Target Rs 460
Bernstein initiated a rating on Delhivery with a target price of Rs 460. The global investment bank is bullish on recovery in earnings and cash flows and continued benefit from being low-cost.

It sees a rebound to high teen growth this year. Part truck load (B2B) business is recovering. The company hikes EBITDA estimates by 25-59% for FY24/25.

ICICI Securities on Suzlon: Initiate Buy| Target Rs 22
ICICI Securities initiated coverage on Suzlon with a buy rating and a target price of Rs 22. Suzlon is a market leader by wide margins.

“There is a sharp improvement in the industry outlook. We expect market growth at 35% CAGR. A repaired balance sheet: leverage is a relic of the past,” the brokerage said.

(Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)